ZA858157B - Immunogenic complex,a method for producing the same,and the use thereof as an immune stimulant,vaccines and reagents - Google Patents

Immunogenic complex,a method for producing the same,and the use thereof as an immune stimulant,vaccines and reagents

Info

Publication number
ZA858157B
ZA858157B ZA858157A ZA858157A ZA858157B ZA 858157 B ZA858157 B ZA 858157B ZA 858157 A ZA858157 A ZA 858157A ZA 858157 A ZA858157 A ZA 858157A ZA 858157 B ZA858157 B ZA 858157B
Authority
ZA
South Africa
Prior art keywords
peptides
proteins
reagents
carrier molecule
vaccines
Prior art date
Application number
ZA858157A
Other languages
English (en)
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein filed Critical Bror Morein
Publication of ZA858157B publication Critical patent/ZA858157B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA858157A 1984-11-01 1985-10-23 Immunogenic complex,a method for producing the same,and the use thereof as an immune stimulant,vaccines and reagents ZA858157B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8405493A SE8405493D0 (sv) 1984-11-01 1984-11-01 Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel

Publications (1)

Publication Number Publication Date
ZA858157B true ZA858157B (en) 1986-06-25

Family

ID=20357588

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA858157A ZA858157B (en) 1984-11-01 1985-10-23 Immunogenic complex,a method for producing the same,and the use thereof as an immune stimulant,vaccines and reagents

Country Status (17)

Country Link
US (1) US5254339A (fr)
EP (2) EP0180564B1 (fr)
JP (2) JPH07116056B2 (fr)
AT (1) ATE65186T1 (fr)
AU (2) AU589915B2 (fr)
CA (2) CA1275042A (fr)
DE (1) DE3583485D1 (fr)
DK (1) DK166653B1 (fr)
ES (1) ES8701497A1 (fr)
FI (1) FI86801C (fr)
IE (1) IE58530B1 (fr)
NO (1) NO167076C (fr)
NZ (1) NZ213899A (fr)
PT (1) PT81384B (fr)
SE (1) SE8405493D0 (fr)
WO (1) WO1987002250A1 (fr)
ZA (1) ZA858157B (fr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (fr) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentialisation
FR2598434B1 (fr) * 1986-05-12 1988-09-16 Pf Medicament Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
EP0270295A3 (fr) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Vaccin conjugué
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
FR2614306B1 (fr) * 1987-04-22 1989-07-28 Pf Medicament Nouveau derive de d.25, procede de preparation, utilisation a titre d'agent immunostimulant et compositions pharmaceutiques le contenant.
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
JPH049015U (fr) * 1990-05-09 1992-01-27
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
EP0604727A1 (fr) * 1992-12-31 1994-07-06 American Cyanamid Company Immunogénéité améliorée d'un vaccin par incorporation d'un cytocine dans un complexe immunostimulant contenant un antigène
CA2158651C (fr) * 1993-03-29 2009-09-01 David S. Roberts Vaccins clostridiaux a plusieurs composantes, utilisant des adjuvants a base de saponine
JPH0756123A (ja) * 1993-08-20 1995-03-03 Nakanishi Opt:Kk 眼鏡フレーム
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0805855B1 (fr) * 1995-01-27 2007-02-28 Genencor International, Inc. Procede d'extraction au moyen d'un enzyme tensioactif
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US20030190323A1 (en) * 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
KR100523685B1 (ko) 1997-08-04 2005-10-26 가부시끼가이샤 센탈 세메 가가꾸 겐꾸쇼 Ｃ형 간염 바이러스의 코어 영역의 아미노산 서열을 인지하는 모노클로날 항체
ID29082A (id) * 1998-09-22 2001-07-26 Molecular Express Inc Komposisi liposom imunogenik
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2000061724A2 (fr) 1999-04-09 2000-10-19 Pharmacia & Upjohn Company Compositions vaccinales anti-bacteriennes
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
EP1360315A2 (fr) 2000-04-06 2003-11-12 PHARMACIA & UPJOHN COMPANY Procedes et materiaux antimicrobiens
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2002030542A2 (fr) 2000-10-12 2002-04-18 Robert Corcoran Purification de substances par chromatographie d'affinite de reaction
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60327925D1 (de) * 2002-03-01 2009-07-23 Gary Levy Verwendung von löslichem fgl2 als immunosuppressivum
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US7601804B2 (en) 2002-08-12 2009-10-13 Intervet International B.V. Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
EP1578443B1 (fr) 2002-11-20 2011-01-12 Bestewil Holding B.V. Compositions comprenant des complexes d'antigenes, leur procede de fabrication ainsi que des procedes d'utilisation desdits complexes d'antigenes pour la vaccination
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
CA2612271A1 (fr) 2005-06-16 2006-12-21 Universiteit Gent Vaccins d'immunisation contre helicobacter
ATE496629T1 (de) 2005-07-28 2011-02-15 Pfizer Prod Inc Impfstoff gegen felines calicivirus (fcv), der ein fcv kapsid protein oder ein isoliertes fcv kapsid protein mit der protein sequenz seq id no: 13 oder mit einer protein sequenz, die zumindestens zu 95 identisch zur seq id no: 13 ist enthält.
NZ566490A (en) 2005-10-07 2011-06-30 Pfizer Prod Inc Live attenuated or killed H3N8 influenza vaccines and methods to treat canine influenza
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HUE062920T2 (hu) 2006-12-27 2023-12-28 Zoetis Services Llc Eljárások vakcina beadására
EP3381445B1 (fr) 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
AU2008340319A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
KR101691574B1 (ko) 2008-12-09 2017-01-02 노바백스, 인코포레이티드 변형 ｒｓｖ ｆ 단백질 및 이들의 사용 방법
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102740878A (zh) 2009-10-19 2012-10-17 英特维特国际股份有限公司 链球菌组合疫苗
EP2490716A1 (fr) 2009-10-22 2012-08-29 Universität Leipzig Détection d'un circovirus chez des veaux souffrant de pancytopénie néonatale bovine
EP2560985B1 (fr) 2010-04-21 2016-06-29 Pharmaq AS Séquences d'acide nucléique d'un virus de poisson et leur utilisation
MX340739B (es) 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
PT3170508T (pt) 2010-06-04 2020-01-16 Wyeth Llc Formulações de vacinas
WO2012010290A1 (fr) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Méthodes et compositions de diagnostic et de traitement d'une maladie métabolique
WO2012010291A1 (fr) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Méthodes et compositions de diagnostic et de traitement d'une maladie métabolique
CA2805741C (fr) 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition renfermant une matrice isocom et des ectodomaines
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
WO2012032489A1 (fr) 2010-09-10 2012-03-15 Wyeth Llc Variants non-lipidiques des antigènes orf 2086 de neisseria meningitidis
EP2635593B1 (fr) 2010-11-05 2016-09-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Vaccins pour la prévention d'infections à méningocoque
WO2012066481A1 (fr) 2010-11-15 2012-05-24 Pharmaq As Nouvel agent étiologique
EP2462950A1 (fr) 2010-12-08 2012-06-13 Neovacs Vaccin fortement inactivé mais immunogène hautement stable et son procédé de fabrication
CA2820837A1 (fr) 2010-12-08 2012-06-14 Neovacs Vaccin fortement inactive mais extremement immunogene, et son procede de fabrication
DK2654784T3 (en) 2010-12-22 2017-02-13 Wyeth Llc STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
JP5980810B2 (ja) 2010-12-29 2016-09-07 インターベット インターナショナル ベー． フェー． イヌバベシア症ワクチン抗原
US9139618B2 (en) 2010-12-29 2015-09-22 Intervet Inc. Salmonid alphavirus protein E2
US20140086954A1 (en) 2011-03-31 2014-03-27 Chu De Toulouse Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
CN103608031B (zh) 2011-04-07 2016-08-17 尼奥瓦克斯公司 用于治疗IFNα相关病况的方法
EP2508197A1 (fr) 2011-04-07 2012-10-10 Neovacs Procédés de traitement de conditions associées à IFN alpha
ES2639122T3 (es) 2011-05-13 2017-10-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
RU2565827C2 (ru) * 2011-07-20 2015-10-20 Эбботт Байолоджикалз Б.В. Способ получения вирусного антигена и вакцин
AU2012306282A1 (en) 2011-09-08 2014-03-20 Umc Utrecht Holding B.V. Vaccine based on Staphylococcal superantigen-like 3 protein (SSL3)
JP6050822B2 (ja) 2011-10-03 2016-12-21 モレインクス，エービー ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
CA2865745C (fr) 2012-03-09 2018-01-09 Pfizer Inc. Compositions de neisseria meningitidis et procedes associes
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014018274A1 (fr) 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprenant des molécules ospa chimériques et leurs procédés d'utilisation
ES2933127T3 (es) 2012-12-20 2023-02-01 Pfizer Procedimiento de glucoconjugación
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CA2907571A1 (fr) 2013-03-26 2014-10-02 The Pirbright Institute Capsides fmdv stabilises
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160077214A (ko) 2013-12-16 2016-07-01 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
WO2016130569A1 (fr) 2015-02-09 2016-08-18 Mj Biologics, Inc. Composition contenant des antigènes du vdep et procédés de fabrication et d'utilisation de la composition
ES2702325T3 (es) 2014-03-11 2019-02-28 Univ Minnesota Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
MX379510B (es) 2014-09-03 2025-03-10 Intervet Int Bv Coronavirus bovino atenuado y vacunas relacionadas.
US10493147B2 (en) 2014-10-03 2019-12-03 Intervet Inc. Broad-spectrum vaccine against avian reovirus
EA201790558A1 (ru) 2014-10-15 2017-08-31 Ксенотера Композиция с пониженной иммуногенностью
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107533060B (zh) 2015-03-10 2019-11-05 生物辐射实验室股份有限公司 组合密螺旋体和非密螺旋体梅毒测试
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
WO2018035199A1 (fr) 2016-08-17 2018-02-22 Pharmaq As Vaccin contre le pou du poisson
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112020005229A2 (pt) 2017-09-18 2020-09-24 Bayer Healthcare Llc métodos de inativação de vírus usando n-metilglucamida e seus derivados
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
EP4034157A1 (fr) 2019-09-27 2022-08-03 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US12570700B2 (en) 2020-04-17 2026-03-10 Regents Of The University Of Minnesota SARS-CoV-2 spike receptor binding domain and compositions and methods thereof
EP3922255A1 (fr) 2020-06-10 2021-12-15 Prokarium Limited Thérapie du cancer
CA3192786A1 (fr) 2020-08-26 2022-03-03 Pfizer Inc. Conjugues polysaccharide-proteine de streptococcus du groupe b, procedes de production de conjugues, compositions immunogenes comprenant les conjugues et leurs utilisations
WO2022136505A1 (fr) 2020-12-23 2022-06-30 Xenothera Composition d'anticorps polyclonal de porc destinée à être utilisée pour traiter et/ou prévenir une libération de cytokine pro-inflammatoire macrophage dépendante d'un anticorps dans une immunothérapie anti-infectieuse passive
EP4124342A1 (fr) 2021-07-28 2023-02-01 Prokarium Limited Thérapie du cancer avec bacteries vivantes attenuees
CN113662950B (zh) * 2021-09-01 2023-03-17 山东省农业科学院畜牧兽医研究所 皂苷在制备抗牛支原体产品中的应用
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
CA3253283A1 (fr) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccins contre moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
JP2025532724A (ja) 2022-09-29 2025-10-03 ファイザー・インク Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
KR20250135177A (ko) 2023-01-18 2025-09-12 노바백스 에이비 사포닌과 지질을 포함하는 입자에 존재하는 사포닌을 정량하는 방법
US20250085282A1 (en) 2023-09-11 2025-03-13 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
WO2025068413A1 (fr) 2023-09-28 2025-04-03 Prokarium Limited Variants d'interleukine 18
WO2025068401A1 (fr) 2023-09-28 2025-04-03 Prokarium Limited Variant d'interleukine 15
WO2025101668A1 (fr) 2023-11-06 2025-05-15 Novavax, Inc. Compositions immunogènes intranasales
WO2025109155A1 (fr) 2023-11-24 2025-05-30 Prokarium Limited Variant d'interleukine
WO2025224251A1 (fr) 2024-04-24 2025-10-30 Prokarium Limited Micro-organismes modifiés
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape
WO2025264964A1 (fr) 2024-06-20 2025-12-26 Zoetis Services Llc Vaccins contre tenacibaculum finnmarkense
WO2026022584A1 (fr) 2024-07-22 2026-01-29 Glaxosmithkline Biologicals Sa Méthodes de retardement de la démence

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
GB2104527B (en) * 1981-08-24 1985-10-02 Vilas V Likhite Antingens as immunostimulant adjuvants
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1984003506A1 (fr) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Sequences d'acides amines antigeniquement actives
EP0142193A1 (fr) * 1983-10-22 1985-05-22 Akzo N.V. Préparation d'immunogènes comprenant des antigènes et/ou des déterminants antigéniques liés à des supports contenant des glycosides
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3617978A1 (de) * 1986-05-28 1987-12-03 Bayer Ag Verzweigte thermoplastische polycarbonate mit verbessertem schutz gegen uv-licht
US6578143B1 (en) * 1998-12-18 2003-06-10 Qualcomm Incorporated Method for negotiating weakened keys in encryption systems
FR2788649A1 (fr) * 1999-01-18 2000-07-21 Schlumberger Systems & Service Procede de chargement securise de donnees entre des modules de securite
FI20075083A0 (fi) * 2007-02-06 2007-02-06 Nokia Corp Ilmaisumenetelmä ja -laite monivuo-MIMOa varten

Also Published As

Publication number Publication date
EP0242380A1 (fr) 1987-10-28
CA1275246C (fr) 1990-10-16
JPH07116056B2 (ja) 1995-12-13
DK166653B1 (da) 1993-06-28
AU6475286A (en) 1987-05-05
FI854158L (fi) 1986-05-02
JPS61129136A (ja) 1986-06-17
WO1987002250A1 (fr) 1987-04-23
FI854158A0 (fi) 1985-10-23
IE852672L (en) 1986-05-01
JPH0751514B2 (ja) 1995-06-05
NO167076C (no) 1991-10-02
FI86801C (fi) 1992-10-26
US5254339A (en) 1993-10-19
ES8701497A1 (es) 1986-12-01
ATE65186T1 (de) 1991-08-15
AU589915B2 (en) 1989-10-26
FI86801B (fi) 1992-07-15
SE8405493D0 (sv) 1984-11-01
CA1275042A (fr) 1990-10-09
NO854355L (no) 1986-05-02
EP0180564A3 (en) 1988-06-01
EP0242380B1 (fr) 1991-04-03
AU4938385A (en) 1986-05-08
EP0180564A2 (fr) 1986-05-07
PT81384A (en) 1985-11-01
IE58530B1 (en) 1993-10-06
NO167076B (no) 1991-06-24
EP0180564B1 (fr) 1991-07-17
AU590904B2 (en) 1989-11-23
PT81384B (pt) 1987-11-11
DE3583485D1 (de) 1991-08-22
JPS63501078A (ja) 1988-04-21
NZ213899A (en) 1988-10-28
DK498585D0 (da) 1985-10-30
DK498585A (da) 1986-05-02
ES548412A0 (es) 1986-12-01

Similar Documents

Publication Publication Date Title
AU589915B2 (en) Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents
IE832394L (en) Immunogenic protein or peptide complex vaccine.
Martin et al. The chromatographic fractionation of ribonuclease
Furukawa et al. Co-purification of galactosyltransferases from chick-embryo liver
Williamson et al. The chemical composition of trypanosomes. III. Antigenic constituents of Brucei trypanosomes
Khan et al. Thermodynamic and kinetic analysis of carbohydrate binding to the basic lectin from winged bean (Psophocarpus tetragonolobus).
SU968036A1 (ru) Способ получени меченого белка
Fishkin et al. Isolation of a glycoprotein from granulation tissue in rats
DE2102514A1 (de) Verfahren zur chemischen Kupplung biologisch aktiver Stoffe an oxiran haltige Polymere
Latner et al. Preparation of highly potent intrinsic factor mucoprotein
Barraco et al. Paleobiochemical analysis of an Egyptian mummy
Shin et al. Intersubunit disulfides of the follitropin receptor.
Palmer et al. Nonspecific precipitation of serum proteins by sodium lauryl sulfate in agar diffusion and immunoelectrophoresis
SLOMIANY et al. ABH‐Blood‐Group Antigens and Glycolipids of Human Saliva
Irie et al. Immunological studies on mouse mammary tumors. V. Chemical analysis of further purified tumorspecific antigen of mouse mammary tumor
Chen et al. Neoglycoproteins: preparation of noncovalent glycoproteins through high-affinity protein-(glycosyl) ligand complexes
Hammond et al. Modification of meningococcal polysaccharide antigens for use in passive hemagglutination tests
Bogoch et al. Dialysable neuraminic acid in human cerebrospinal fluid
Mikhailov et al. Immunochemical study of gangliosides at the cell surface of sea urchin embryos
Alvarado Quiroz Characterization of marine exopolymeric substance (EPS) responsible for binding of thorium (IV) isotopes
SHARON et al. Studies on the interaction of lectins with saccharides on lymphocyte cell surfaces
Quiroz Characterization of Marine Exopolymeric Substance (EPS) Responsible for Binding of Thorium (IV) Isotopes
HONG et al. Antilymphocyte Globulin Therapy for Aplastic Anemia in Children
Rayet Analysis of the aminoglycosides neomycin and streptomycin
DK302987A (da) Fremgangsmaade til fremstilling af et immunogent kompleks